tiprankstipranks
Advertisement
Advertisement

REGN Stock Latest News

Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors
Company AnnouncementsRegeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors
3d ago
REGN
Regeneron price target raised to $1,000 from $995 at Guggenheim
PremiumThe Fly
Regeneron price target raised to $1,000 from $995 at Guggenheim
3d ago
REGN
Regeneron Pharmaceuticals Lawsuit Focuses on Trial Disclosures and REGN Stock Drops 
PremiumClass Action
Regeneron Pharmaceuticals Lawsuit Focuses on Trial Disclosures and REGN Stock Drops 
3d ago
REGN
Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know
PremiumCompany Announcements
Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know
4d ago
REGN
Biohaven enters into clinical supply agreement with Regeneron
PremiumThe Fly
Biohaven enters into clinical supply agreement with Regeneron
4d ago
BHVN
REGN
Regeneron’s dupilumab granted orphan drug designation
PremiumThe FlyRegeneron’s dupilumab granted orphan drug designation
9d ago
REGN
Regeneron price target lowered to $856 from $860 at BofA
Premium
The Fly
Regeneron price target lowered to $856 from $860 at BofA
11d ago
REGN
Regeneron: Buy Rating Reaffirmed as Analyst Trims Eylea HD Forecasts and Lowers Price Target to $856 on Pipeline-Driven Upside Potential
Premium
Ratings
Regeneron: Buy Rating Reaffirmed as Analyst Trims Eylea HD Forecasts and Lowers Price Target to $856 on Pipeline-Driven Upside Potential
11d ago
REGN
Regeneron price target lowered to $854 from $855 at Piper Sandler
PremiumThe Fly
Regeneron price target lowered to $854 from $855 at Piper Sandler
15d ago
REGN
Regeneron price target lowered to $730 from $788 at Morgan Stanley
PremiumThe Fly
Regeneron price target lowered to $730 from $788 at Morgan Stanley
16d ago
REGN
Regeneron price target lowered to $769 from $778 at Truist
PremiumThe Fly
Regeneron price target lowered to $769 from $778 at Truist
17d ago
REGN
Regeneron price target lowered to $696 from $707 at RBC Capital
PremiumThe Fly
Regeneron price target lowered to $696 from $707 at RBC Capital
17d ago
REGN
Regeneron price target lowered to $800 from $990 at HSBC
PremiumThe FlyRegeneron price target lowered to $800 from $990 at HSBC
18d ago
REGN
Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald
Premium
The Fly
Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald
18d ago
REGN
FDA selects seven participants for PreCheck Pilot Program
Premium
The Fly
FDA selects seven participants for PreCheck Pilot Program
24d ago
LLY
AMRX
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
PremiumThe Fly
Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says
24d ago
LLY
AMRX
Regeneron Expands Metabolic Footprint With New Phase 2a Fatty Liver Study
PremiumCompany Announcements
Regeneron Expands Metabolic Footprint With New Phase 2a Fatty Liver Study
28d ago
REGN
Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways
PremiumCompany Announcements
Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways
29d ago
REGN
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
PremiumThe Fly
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
1M ago
ABBV
APGE
Regeneron announces FDA, EMA accept cemdisiran submissions for review
PremiumThe FlyRegeneron announces FDA, EMA accept cemdisiran submissions for review
1M ago
REGN
AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo
Premium
The Fly
AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo
1M ago
ABBV
APGE
‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition
Premium
Market News
‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition
1M ago
SNY
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >